CJC-1295 with DAC vs Retatrutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both CJC-1295 with DAC and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 with DAC Retatrutide
Weight 3,647.28 Da 4,731.33 Da
Half-life 6-8 days ~6 days
Chain 30 amino acids 39 amino acids
Type GHRH analog with DAC Triple GLP-1/GIP/glucagon agonist
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
CJC-1295 with DAC Retatrutide
Status Well Studied Extensively Studied
References 4 studies 6 studies
Latest 2025 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.